{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:46:43Z","timestamp":1788637603164,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012965","name":"Mount Royal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012965","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104751","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T19:16:25Z","timestamp":1745867785000},"page":"104751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering"],"prefix":"10.1016","volume":"211","author":[{"given":"Anuupama","family":"Suchiita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash Chandra","family":"Sonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2025.104751_bib1","doi-asserted-by":"crossref","DOI":"10.1080\/17441692.2020.1825769","article-title":"Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah","volume":"17","author":"Abbas","year":"2022","journal-title":"Glob. Public Health"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104751_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/pon.5674","article-title":"Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy","volume":"30","author":"Barata","year":"2021","journal-title":"Psycho-Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104751_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2021.02.006","article-title":"Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy","volume":"54","author":"Beauvais","year":"2021","journal-title":"J. Microbiol., Immunol. Infect."},{"issue":"10266","key":"10.1016\/j.critrevonc.2025.104751_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03193-7","article-title":"Establishment and validation of in-house cryopreserved CAR\/TCR-T cell flow cytometry quality control","volume":"19","author":"Cai","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104751_bib6","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104751_bib7","article-title":"Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2022.10.001","article-title":"Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed\/Refractory Multiple Myeloma in the CARTITUDE-1 Study","volume":"23","author":"Cohen","year":"2023","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104751_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020403","article-title":"Nanobody based dual specific CARs","volume":"19","author":"De Munter","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104751_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104751_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104751_bib12","doi-asserted-by":"crossref","DOI":"10.20517\/2394-4722.2022.51","article-title":"Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)","volume":"8","author":"D\u2019Souza","year":"2022","journal-title":"J. Cancer Metastas-.-. Treat."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104751_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med."},{"issue":"OCT","key":"10.1016\/j.critrevonc.2025.104751_bib15","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104751_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2017.06.014","article-title":"Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors","volume":"17","author":"Gay","year":"2017","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010152","article-title":"Evaluation of production protocols for the generation of ny-eso-1-specific t cells","volume":"10","author":"Gong","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2025.104751_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"eBioMedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104751_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T Therapies in Solid Tumors: Opportunities and Challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104751_bib20","doi-asserted-by":"crossref","DOI":"10.7150\/jca.48976","article-title":"Current progress in CAR-T cell therapy for hematological malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104751_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104751_bib22","doi-asserted-by":"crossref","DOI":"10.18609\/cgti.2018.030","article-title":"Ethical Considerations in the Translation of CAR-T Cell Therapies","volume":"4","author":"Imbach","year":"2018","journal-title":"Cell Gene Ther. Insights"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104751_bib23","article-title":"Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma","volume":"138","author":"Jagannath","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104751_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104751_bib25","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","author":"Jain","year":"2023","journal-title":"Blood (Vol. 141, Issue 20)."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104751_bib26","article-title":"Research Progress of Multi-target CAR-T Cell Therapy for Cancer","volume":"49","author":"Jiang","year":"2022","journal-title":"Cancer Res. Prev. Treat."},{"key":"10.1016\/j.critrevonc.2025.104751_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK Cells: From Natural Basis to Design for Kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104751_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.04.005","article-title":"Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor","volume":"29","author":"Lain\u0161\u010dek","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104751_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104751_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from car t-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.critrevonc.2025.104751_bib32","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"19","author":"Martin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104751_bib33","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"10.1016\/j.critrevonc.2025.104751_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: A scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104751_bib35","article-title":"State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses","volume":"27","author":"Meir","year":"2021","journal-title":"Transplant. Cell. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104751_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104751_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104751_bib38","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0646","article-title":"EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma","volume":"25","author":"Papadouli","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104751_bib39","article-title":"Effects of CAR structure and culture conditions on memory CAR-T cells","volume":"25","author":"Pei","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104751_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104751_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2018-316595","article-title":"Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma","volume":"68","author":"Raj","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib42","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104751_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/cas.15556","article-title":"Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort","volume":"113","author":"Ri","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104751_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.822298","article-title":"Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy","volume":"13","author":"Ruppel","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory DLBCL","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104751_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/14712598.2018.1473368","article-title":"Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities","volume":"18","author":"Shum","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104751_bib47","unstructured":"Squibb, B.M. (2021). CAR T Cell Therapy for R\/R Multiple Myeloma ABECMA\u00ae (idecabtagene vicleucel). In ABECMA\u00ae (idecabtagene vicleucel) Patient Site."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104751_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104751_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104751_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104751_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104751_bib52","first-page":"391","article-title":"Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer","author":"Wang","year":"2023","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib53","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104751_bib54","article-title":"Determination of the biodistribution of chimeric antigen receptor-modified T cells against CD19 in NSG mice","volume":"167","author":"Wen","year":"2022","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.critrevonc.2025.104751_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807915","article-title":"Single-cell RNA-Seq reveals the potential risk of anti-mesothelin CAR T Cell therapy toxicity to different organs in humans","volume":"13","author":"Wen","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104751_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23446","article-title":"Cbl induced ubiquitination of HER2 mediate immune escape from HER2-targeted CAR-T","volume":"37","author":"Yang","year":"2023","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.critrevonc.2025.104751_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104751_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-021-02486-x","article-title":"Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses","volume":"20","author":"Zarezadeh Mehrabadi","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104751_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1325860","article-title":"Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report","volume":"15","author":"Zhong","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:28:52Z","timestamp":1762352932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":60,"alternative-id":["S1040842825001398"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104751","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104751"}}